Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma
Authors:
- Yichi ZhangYZYichi Zhang
- Marjaana OjalillMOMarjaana Ojalill
- Antonia BoyerABAntonia Boyer
- Xiao Lei ChenXCXiao Lei Chen
- Elise TahonETElise Tahon
- Gaëtan Thivolle LiouxGLGaëtan Thivolle Lioux
- Marvin XiaMXMarvin Xia
- Maryam AbbasMAMaryam Abbas
- Halime Meryem SoyluHSHalime Meryem Soylu
- Douglas B. FliederDFDouglas B. Flieder
- Denise C. ConnollyDCDenise C. Connolly
- Alfredo A. MolinoloAMAlfredo A. Molinolo
Open Access
- 1 December 2024
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 4 (12) , 3165-3179
Abstract
Tumor chemotherapy resistance arises frequently and limits high-grade serous ovarian cancer (HGSOC) patient survival. Focal adhesion kinase (FAK) is an intracellular protein–tyrosine kinase encoded by PTK2, a gene that is often gained in HGSOC. Canonically, FAK functions at the cell periphery. However, FAK also transits to the nucleus to modulate gene expression. We find that FAK is tyrosine-phosphorylated and nuclear-localized in tumors of patients with HGSOC surviving neoadjuvant platinum–paclitaxel chemotherapy and that FAK nuclear accumulation occurs upon subcytotoxic cisplatin exposure to ovarian tumor cells in vitro. FAK nuclear localization sequence (NLS) mutational inactivation resulted in tumor cell sensitization to cisplatin in vitro and in vivo relative to wild-type FAK-reconstituted ovarian tumor cells. Cisplatin cytotoxicity was associated with elevated ERK MAPK activation in FAK NLS− cells, cisplatin-stimulated ERK activation was also enhanced upon loss of FAK activity or expression, and cisplatin-stimulated cell death was prevented by an inhibitor of ERK signaling. MAPK phosphastase-1 (MKP1) negatively regulates ERK signaling, and cisplatin-induced MKP1 levels were significantly elevated in wild-type FAK compared with FAK NLS− ovarian tumor cells. Notably, small-molecule MKP1 inhibition enhanced both cisplatin-stimulated ERK phosphorylation and ovarian tumor cell death. Together, our results show that FAK expression, activity, and nuclear localization limit cisplatin cytotoxicity in part by regulating MKP1 levels and preventing noncanonical ERK/MAPK activation. Significance: FAK inhibitors are in combinatorial clinical testing with agents that prevent Ras–Raf–MAPK pathway activation in various cancers. This study suggests that nuclear FAK limits ERK/MAPK activation in supporting HGSOC cell survival to cisplatin stress. Overall, it is likely that targets of FAK-mediated survival signaling may be tumor type– and context-dependent.Keywords
All Related Versions
This publication has 40 references indexed in Scilit:
- Nuclear FAK Promotes Cell Proliferation and Survival through FERM-Enhanced p53 DegradationMolecular Cell, 2008
- ERK-Dependent MKP-1–Mediated Cisplatin Resistance in Human Ovarian Cancer CellsCancer Research, 2007
- Mitogen-Activated Protein Kinase Phosphatase-1 Is Required for Cisplatin ResistanceCancer Research, 2006
- Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumorsOncogene, 2006
- Focal adhesion kinase: in command and control of cell motilityNature Reviews Molecular Cell Biology, 2005
- Ovarian cancer: strategies for overcoming resistance to chemotherapyNature Reviews Cancer, 2003
- Expression of mitogen‐activated protein kinase phosphatase‐1 (MKP‐1) in primary human ovarian carcinomaInternational Journal of Cancer, 2002
- Requirement for ERK Activation in Cisplatin-induced ApoptosisJournal of Biological Chemistry, 2000
- Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic–nuclear transportProceedings of the National Academy of Sciences, 1996
- Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinaseNature, 1994